Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 2Ovarian Diseases 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × NUC-1031 × Gynecologic × Clear all
NCT02303912 2021-05-18

ProGem2

Imperial College Healthcare NHS Trust

Phase 1 Completed
25 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03146663 2021-02-21

NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

NuCana plc

Phase 2 Terminated
53 enrolled 19 charts
Gynecologic

Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡